Objective-Triglyceride-rich lipoproteins have emerged as causal risk factors for developing coronary heart disease independent of low-density lipoprotein cholesterol levels. Apolipoprotein C-III (ApoC-III) modulates triglyceride-rich lipoprotein metabolism through inhibition of lipoprotein lipase and hepatic uptake of triglyceride-rich lipoproteins.
C urrently, the paradigm for the prevention and treatment of coronary heart disease (CHD) is lowering circulating low-density lipoprotein cholesterol (LDL-C) through statins and other therapies. 1 Although statins are highly efficacious in lowering LDL-C and vascular risk, significant residual risk remains for many. Also, many at-risk patients are intolerant to the adverse effects of these drugs. Plasma TG have emerged as independent predictor of cardiovascular risk, as evidenced by multiple prospective epidemiological studies. 2, 3 Recent human genetics studies have given credence to the concept that triglyceride-rich lipoproteins (TRLs) may be causally related to cardiovascular risk. 4, 5 Genetic variation in several genes in the lipoprotein lipase pathway of plasma triglyceride hydrolysis is associated with triglyceride levels and CHD risk. [6] [7] [8] [9] [10] Among the genes implicated in these studies is APOC3, which encodes apolipoprotein C-III (ApoC-III). 4, 6, 7 ApoC-III is a small protein (8.8 kDa) that is secreted from the liver and small intestine. 11 ApoC-III circulates in the blood on very LDLs (VLDLs), chylomicrons, and high-density lipoproteins (HDLs). Animal models and biochemical studies have shown that ApoC-III inhibits the turnover of plasma triglycerides through potentially multiple synergistic mechanisms, including inhibition of lipoprotein lipase activity, delay of hepatic clearance of TRLs, and promotion of VLDL secretion. [12] [13] [14] [15] [16] [17] [18] In humans, genetic loss-of-function of APOC3 is associated with lower plasma triglycerides and a reduced risk of CHD and coronary calcification. 6, 7, 19 Investigations of rare coding variants in APOC3 have shown that CHD-protective variants reduce circulating ApoC-III levels. These studies suggest that inhibition of ApoC-III may reduce vascular risk.
The molecular regulation of ApoC-III expression and circulating levels in metabolic disease states is complex. Several nutrient-and metabolite-activated hepatic transcription factors, including HNF4α (hepatocyte nuclear factor 4 alpha), PPARα (peroxisome proliferator-activated receptor alpha), Rev-Erbα (nuclear receptor subfamily 1, group D, member 1 [NR1D1]), RORα (retinoic acid receptor [RAR]-related orphan receptor alpha), and FXR, may either positively or negatively regulate Apoc3 transcription in rodent hepatocytes. 17, [20] [21] [22] [23] [24] [25] [26] [27] Studies in a mouse model of insulin resistance demonstrated that Apoc3 gene expression increases in response to glucose via HNFα-and ChrEBP (carbohydrate response element binding protein)-mediated transcription. 27 Apoc3 expression decreases with insulin or fibrate stimulation in vitro. 20, 22, 26, 28 However, plasma ApoC-III levels are not correlated with plasma insulin in humans. 17, 27 It has been suggested that glucose-mediated induction and insulin-mediated suppression of hepatic APOC3 expression may normally balance each other to regulate the total amount of ApoC-III secreted from the liver. 17, 27 Likewise, in the insulin-resistant state, the sensitivity of APOC3 expression to insulin may be lost and in the concomitant setting of hyperglycemia there may be unopposed activation of APOC3 expression and increased ApoC-III secretion on TRLs. This mechanism of perturbed TRL metabolism may modulate insulin resistance and cardiovascular risk in multifaceted ways.
The majority of studies of ApoC-III, triglycerides, and CHD risk to date have been conducted in nondiabetic subjects. However, CHD is prevalent in patients with type 2 diabetes mellitus (T2DM) and is indeed the leading cause of death in this population. 29 Insulin resistance and T2DM are characterized by alterations in TRL metabolism. 30 In addition, the expression of APOC3 is regulated by both insulin and glucose. 17, 20, 22, 27, 28 Thus, the relationship of ApoC-III to TRL metabolism and CHD in T2DM is of substantial importance. Here, we studied a sample of 1422 subjects with T2DM but without clinical CHD for the relationship of plasma ApoC-III levels with triglycerides, related metabolic biomarkers, and coronary artery calcification (CAC), a measure of subclinical atherosclerosis.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Characteristic of Participants
The characteristics of the study population are described in Table 1 . Study participants (n=1422) were predominantly males of white descent. Subjects had a median age of 59 years at the time of enrollment. Mean plasma ApoC-III levels were 12.5±10 mg/dL, with a median of 11.3 mg/dL (Figure 1 ). Subjects of African ancestry had lower ApoC-III levels than those of European ancestry (10.9±12.4 versus 13.5±10; P<1×10 −3 , Table 1; Table I in the online-only Data Supplement) . ApoC-III levels were significantly lower in women than men (11.8±11 versus 13±10 mg/dL; P<0.05; Table 1 ).
Association of ApoC-III Levels With Lipid-Related Traits
We found a significant positive association of ApoC-III levels with triglycerides (Spearman correlation coefficient r=0.59; P<1×10 −4 ; Table 2 ). This association remained significant even after adjusting for age, sex, race, body mass index (BMI), alcohol use, glomerular filtration rate, exercise, use of lipid-lowering, and hypoglycemic medications in a linear regression analysis model (β=0.57; P<1x10 −4 ; Table 3 ). In a multivariate linear regression model stratified by sex, we found that triglyceride levels were significantly associated with ApoC-III levels in both sexes (women, β=0.53; P<1×10 −4 and men, β=0.60; P<1×10 −4 ; Table 3 ). We found a positive correlation of ApoC-III levels with plasma levels of total cholesterol (Spearman correlation coefficient r=0.36; P<1×10 ; Table 2 ). These findings were significant after adjusting for age, sex, race, BMI, smoking, alcohol use, and use of lipid-lowering, and hypoglycemic medications in linear regression (Table II in Table 2 ). After adjustment for age, sex, and race, the association between ApoC-III levels with HDL-C attenuated but the association with ApoA-I remained significant (Table II in 
Relationship of ApoC-III Levels With Glycemic and Metabolic Traits
Plasma ApoC-III levels correlated positively with glycosylated hemoglobin (Spearman correlation coefficient r=0.12; P<1×10 −5 ) and fasting glucose levels (Spearman correlation coefficient r=0.16; P<1×10 −5 ), 2 metrics of glucose homeostasis (Table 2 ). These associations remained significant after adjusting for age, sex, and race in linear regression (Table III in the online-only Data Supplement). There was no association of ApoC-III levels with plasma fasting insulin. We stratified the analysis of ApoC-III levels with fasting glucose and hemoglobin A1c (HbA1c) by plasma triglyceride levels (Table III in the online-only Data Supplement) and found that the association was significant in subjects with elevated triglycerides (>150 mg/dL) but not in those with normal triglycerides (<150 mg/dL). To determine if this association might be dependent on the effect of ApoC-III on plasma triglycerides, we examined the association of ApoC-III with both HbA1c and fasting glucose before and after adjusting for plasma (Table 4 ). There was no significant association of both HbA1c and fasting glucose with ApoC-III levels after adjusting for triglycerides in both sexes (women, β=−0.006; P=0.86 and men, β=0.05; P=0.37; Table 4 ).
In sex-stratified analysis of the relationship of ApoC-III with waist circumference, we found no association in women (Spearman correlation coefficient r=0.05; P=0.05) but a modest association with increased waist circumference in men (Spearman correlation coefficient r=0.07; P=0.03; Table 2 ). However, ApoC-III levels were not significantly associated with BMI in the combined sample (Spearman correlation coefficient r=−0.01; P=0.70; Table 2 ).
Association of ApoC-III Levels With CAC
In age, sex, and race-adjusted Tobit conditional regression of ln (CAC+1 ; Table 5 ), higher plasma ApoC-III was also 
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Consistent with analysis of ApoC-III as a continuous variable, Tobit regression of plasma ApoC-III quartiles showed that subjects within the highest ApoC-III quartile had a significantly greater likelihood of increased CAC when compared with subjects in the lowest ApoC-III quartile ( Figure 2 ). These results were comparable in both the combined and sex-stratified analyses for both sexes ( 
Discussion
In this study, we evaluated the relationship of plasma ApoC-III levels to plasma lipids, additional cardiometabolic phenotypes, and CAC in patients with T2DM. Because insulin resistance, perturbed TRL metabolism and increased CHD risk are hallmarks of T2DM, ApoC-III may play a particularly important role in risk of heart disease in this population. As anticipated, we found strong positive relationships between plasma ApoC-III and triglycerides, total cholesterol, ApoB and ApoE levels, and a negative relationship between HDL-C and ApoA-I levels. We also found a significant positive, triglyceride-dependent relationship between ApoC-III and fasting glucose and HbA1c. Finally, we demonstrate a robust association of ApoC-III levels with higher CAC scores and further show that this relationship is attenuated after adjustment for triglycerides or VLDL-C, suggesting that TRLs play an intermediary role in the relationship of ApoC-III with atherosclerosis. This study represents the largest investigation to date evaluating the relationship between plasma ApoC-III levels, markers of cardiometabolic risk, and atherosclerosis in T2DM.
Here, we further advance the proposed relationship between ApoC-III, triglycerides, and atherosclerotic burden in patients with T2DM by evaluating diabetic subjects without preexisting CHD. CAC is an established preclinical marker and predictor of clinical CHD and future cardiac events in both the general population and in patients with T2DM. [31] [32] [33] It has been previously shown that CAC scores >100 robustly predict risk of coronary events in patients >7-fold relative to no CAC, as per the Agatston scoring criteria for CAC, and this relationship is consistent across different ethnicities. 32 We found that when we separated subjects in our study by Apo indicates apolipoprotein; BMI, body mass index; HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; and LDL-C, low-density lipoprotein cholesterol.
*Triglyceride levels were log-transformed because baseline values were not normally distributed. ApoC-III quartile, the highest ApoC-III quartile had higher CAC scores than the lowest ApoC-III quartile, whose scores were largely 0. Thus, we posit that those subjects in the highest ApoC-III quartile would possess a substantially greater risk of CAD relative to those with the lowest ApoC-III levels in our study. Previously, it was suggested that the predominant predictors of CAC progression are age and baseline CAC score beyond traditional risk factors for atherosclerosis. 34 Our study here did not assess the contribution of ApoC-III to the progression of CAC, yet our finding of a robust association of ApoC-III levels with CAC score after correction for multiple important demographic and pharmacological contributors warrants study of the relationship of ApoC-III to the progression of CAC over time and subsequent influence on clinically manifest vascular disease development, particularly in T2DM.
In our analysis of ApoC-III and CAC, adjustment for plasma triglyceride levels attenuated the relationship, implying that plasma ApoC-III relates to CAC in a triglyceridedependent manner. This finding extends those of previous smaller studies evaluating ApoC-III levels and CHD in T2DM. Onat et al 35 showed in 857 subjects with metabolic syndrome that plasma ApoC-III levels positively correlated with multiple inflammatory biomarkers and in men were associated with increased incidence of CHD. Similarly, in a cohort of 188 patients with T2DM, Gervaise et al 36 reported a positive relationship between both total plasma and ApoB-associated ApoC-III levels with triglycerides and with macroangiopathy and incident CHD.
We also found that, such as triglycerides, VLDL-C fully attenuated the association between ApoC-III and CAC in our study. We recently showed that VLDL-C was a predictor of CAC beyond plasma triglycerides in this study population. 37 Indeed, our new findings suggest that the attenuation of the relationship between ApoC-III and CAC may have been more robust after adjusting for VLDL-C than for triglycerides alone. This suggests that ApoC-III may mediate atherosclerotic risk most specifically by contributing to the elevation of remnant cholesterol particles, such as VLDL and chylomicron remnants. This is consistent with its known physiological role in delaying the clearance of TRL remnant particles by the liver through interplay with ApoE on these particles. 13, 14, 17 Our results suggest that inhibition of ApoC-III-mediated elevation of triglycerides and VLDL-C could reduce risk of vascular diseases in the setting of T2DM.
When taken together, our findings support decades of evidence from animal models, biochemical studies, and more recent human genetics studies showing ApoC-III as a key regulator of plasma triglycerides and CHD. Physiological studies in proatherogenic, APOC3-overexpressing mice (APOC3 transgenic; Ldlr knockout mice) showed that ApoC-III could promote atherogenesis in vivo. 38 One previous genotyping study of an APOC3 variant in the Lancaster Amish and 2 recent sequencing studies in large populations identified loss-of-function variants in APOC3 that were associated with lower plasma triglycerides and reduced CAD risk. 6, 7, 19 These 3 studies have established a direct casual genetic role for ApoC-III in mediating cardiovascular risk in humans.
Few studies have evaluated how T2DM modifies the relationship of ApoC-III to CHD risk. Crosby et al 6 attempted to evaluate this in the Framingham Heart Study and the Verona Heart Study as part of their larger exome sequencing effort, which identified APOC3 loss-of-function variants associated with disease protection. They tested the association of ApoC-III levels with incident CHD (Framingham Heart Study) or with cardiovascular mortality (Verona Heart Study). They tested these associations both with a model adjusting for only age and sex or a model that corrected for these in addition to diabetes mellitus, hypertension, LDL-C, HDL-C, lipid-lowering treatment, and fasting glucose. For the Framingham Heart Study, association-testing using the second model with additional covariates including diabetes mellitus attenuated the positive relationship between ApoC-III and incident CHD seen when the first model was used. However, this finding was not replicated in the Verona Heart Study association analysis and inclusion of the additional covariates including diabetes mellitus status only modestly attenuated the association of ApoC-III with cardiovascular mortality. Most importantly, this analysis did not specifically test the contribution of diabetes mellitus to the association between ApoC-III and CHD as multiple other contributors to this relationship were included in the second model. Indeed, T2DM is a multifaceted state of metabolic dysregulation, which may include obesity and hypertriglyceridemia, 2 potential confounders to assessing whether diabetes mellitus alone impacts the relationship of ApoC-III to plasma lipids themselves or to vascular disease risk. Larger studies carefully comparing obese versus nonobese diabetics and hypertriglycerdemic versus normotriglycerdmic diabetics to each other as well as to nondiabetics will be crucial to definitively establish how each metabolic perturbation alters the relationship of ApoC-III to plasma lipids and CHD risk.
Before our study here, several smaller studies have reported that ApoC-III levels are increased with the metabolic syndrome or insulin resistance in humans. In a study of 310 patients with T2DM versus control subjects, Hiukka et al 39 found higher plasma ApoC-III concentrations, higher ratios of ApoC-II-to-ApoC-III, and higher ApoC-III-toApoE of VLDL in T2DM than in nondiabetic subjects. In a study of Cherokee Native American youths, a population predisposed to insulin resistance and increased CHD risk, Blackett et al 40 found positive relationships of apoB-bound Apo indicates apolipoprotein; BMI, body mass index; CAC, coronary artery calcification; CI, confidence interval; CRP, C-reactive protein; VLDL-C, very low-density lipoprotein cholesterol; and TRR, Tobit regression ratio.
*TRR represents the risk of 1 U increase in natural log (CAC+1) for the specified variable. Values with CI that do not cross 0 are considered significant. †Statin, fibrates, niacin, ezetimibe, thiazolidinediones, metformin, sulfonylurea, insulin, exenatide, and sitagliptan. ‡Triglycerides was added to the model as a covariate in addition to age, race, sex, BMI, smoking, alcohol use, GFR, and medications but not in addition to VLDL-C inclusion in this model.
ApoC-III to plasma triglycerides and BMI. In insulin-resistant states, higher plasma ApoC-III is robustly associated with hypertriglyceridemia. van der Ham et al 41 reported higher plasma ApoC-III correlated with higher postprandial triglycerides in a study of 98 men challenged to an oral fat load. Similarly, Lee et al 42 reported in a smaller study of 30 diabetic versus 30 nondiabetic subjects a correlation of total plasma ApoC-III with plasma triglycerides. Despite plasma ApoC-III association with glycemic traits and hypertriglyceridemia in insulin resistance, our data in a much larger T2DM sample than previously reported suggest limited association of ApoC-III with plasma adipokines or with anatomic measures of obesity (BMI and waist circumference) perhaps arguing against a primary ApoC-III modulation of adipose tissue per se.
Supporting the recent genetic studies suggesting ApoC-III loss-of-function is atheroprotective, the direct relationship of ApoC-III to CAC via its modulation of triglycerides and VLDL-C shown by our study implicate ApoC-III as a potential therapeutic target for reduction of vascular disease risk, especially in T2DM. Currently, statins are effective therapeutics for preventing CHD in T2DM subjects, and multiple studies have reported that statins also reduce plasma ApoC-III levels, probably through promoting the clearance of TRLs, as well as LDL from circulation. 43 However, there remains an immense burden of CHD in patients who may already be maximally treated with statins, with ≈1 in 7 patients treated with statins during a 5-year period exhibiting residual cardiovascular disease. 44, 45 Non-HDL-C is the most significant predictor of this on-statin residual vascular risk beyond LDL-C in large meta-analyses of randomized statin trials for reduction of cardiovascular events. 46 There is thus a substantial need for additional synergistic therapies to reduce other causal mediators of CHD, such as non-HDL-C. At least 1 therapy targeting ApoC-III, antisense oligonucleotides silencing hepatic APOC3 expression, is in clinical development. 47 Recently, this therapy was shown to successfully reduce ApoC-III levels and plasma triglycerides in 3 patients with familial chylomicronemia syndrome, a genetic cause of profoundly elevated triglycerides because of lipoprotein lipase deficiency. 48 This work provides 1 example of the use of ApoC-III inhibition for reducing triglycerides in specific clinical settings. Our results suggest there will be great interest in and need to directly evaluate the efficacy of ApoC-III-focused drugs in preventing CHD in high-risk populations particularly those insulinresistant and T2DM.
Our study has both strengths and limitations. We report here the largest evaluation of ApoC-III levels, plasma triglycerides and other lipid and metabolic parameters, and CHD risk in T2DM subjects. Our analysis included significant proportions of non-white ethnicity and women, and we found mostly consistent results for the associations reported across these demographics, suggesting the generalizability of our findings. Limitations of our study include its crosssectional design and lack of additional information on CHDrelated outcomes in these subjects, although CAC has been demonstrated previously to be a reliable predictor of future CHD-related events in T2DM. [31] [32] [33] The use of CAC in monitoring the progression of CHD after incidence and after lipid-lowering therapy is currently being debated, and thus we could not accurately predict how ApoC-III may modulate the progression or regression of disease as measured by this surrogate metric. 49 A large proportion of subjects in our study were on aspirin although they were not necessarily indicated as candidates for primary prevention of cardiovascular events. Because aspirin can modulate risk of atherosclerotic disease, we did test the association of ApoC-III with CAC by Tobit regression modeling after adjusting for aspirin use and observed no attenuation in the association when it was included (data not shown). Because of limited measures and the fact that many of the subjects were on insulin therapy, we did not directly measure homeostatic models of insulin resistance in our patient population, a measure that may have supported our findings of the relationship of ApoC-III to plasma glucose. However, we note consistency in the findings between measures of fasting glucose and HbA1c within our study cohort. Although we did not measure ApoC-III levels in specific lipoprotein subclasses, we show here that total plasma ApoC-III, an easily measurable biomarker in the clinical setting, correlates with plasma triglycerides and apoB in ways that previous studies of lipoprotein-associated ApoC-III levels have suggested, whereas total plasma ApoC-III also associated positively with CAC, a predictor of CHD.
As evidence builds from human genetics and early clinical studies about the value of lowering ApoC-III to reduce cardiovascular risk, it is critical to identify specific high-risk patient populations who would benefit most from ApoC-IIItargeted therapies. Here, we demonstrate convincingly that in T2DM associates with elevated cardiovascular risk factors and greater subclinical atherosclerosis in a manner related to their ApoC-III levels. Thus, therapeutic targeting of ApoC-III in T2DM may provide a powerful tool for reducing the high residual risk of atherosclerotic CHD in this population.
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